1. Home
  2. NUVL vs CPRI Comparison

NUVL vs CPRI Comparison

Compare NUVL & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$103.86

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$25.15

Market Cap

3.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
CPRI
Founded
2017
1981
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
3.2B
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
NUVL
CPRI
Price
$103.86
$25.15
Analyst Decision
Strong Buy
Buy
Analyst Count
15
11
Target Price
$135.00
$26.55
AVG Volume (30 Days)
638.5K
2.9M
Earning Date
10-30-2025
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,369,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$11.86
52 Week High
$112.88
$28.27

Technical Indicators

Market Signals
Indicator
NUVL
CPRI
Relative Strength Index (RSI) 51.36 52.76
Support Level $100.42 $25.05
Resistance Level $107.99 $27.00
Average True Range (ATR) 3.02 0.91
MACD -1.07 -0.27
Stochastic Oscillator 29.85 3.98

Price Performance

Historical Comparison
NUVL
CPRI

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.

Share on Social Networks: